9 articles with Virscio
Virscio Publishes Data Validating Non-Human Primate Model for Testing Chronic Retinal Neovascularization and Vascular Leakage Drug Candidates
Virscio, a translational research company providing definitive, actionable preclinical outcomes through the use of predictive, validated disease models, today announced publication of data that validate a nonhuman primate (NHP) model for testing drug candidates targeting retinal ischemic and neovascular diseases
RxGen to Present Alzheimer’s Disease APP/Abeta Cellular and Animal Models at the Society for Neuroscience’s 49th Annual Meeting
One of the primary challenges in drug development is the inability of preclinical models to reliably predict clinical outcomes.
RxGen, Inc. and miRagen Therapeutics Announce Award of National Institutes of Health (NIH)-National Heart, Lung, and Blood Institute SBIR Grant to Fund Advanced Preclinical Studies Evaluating the Role of microRNAs in Cardiac Disease
RxGen, Inc. and Santaris Pharma A/S Use LNA-antimiR Technology to Antagonize the Liver-expressed microRNA-122 in Non-Human Primates and to Safely Lower Serum Cholesterol
RxGen, Inc. Announces The Formation Of RxGen PrimaTox, Inc., A Subsidiary Focused On Molecular Toxicology In Primates And Humans, Spencer Farr Named CEO